BEIJING, April 22 Lotus Pharmaceuticals,Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growingdeveloper, manufacturer and seller of medicine and drugs in the People'sRepublic of China (the "PRC"), today reported it will exhibit at the 63rdPHARMCHINA.
The Company has attended PHARMCHINA exhibitions every year since 1996 as away to strengthen customer relationships and attract new distributors, whilepromoting its products.
Lotus will continue to market both its self-branded and self-produceddrugs that have established market shares in China. Lotus will also introduceits upcoming innovative asthma drug Laevo-Bambutero, together with two otherpipeline drugs Gliclazide-Controlled Release Tablets for type 2 diabetes andIsosorbide Mononitrate-Sustained Release Tablets for coronary artery disease.
PHARMCHINA has been the largest and most recognized exhibition in theChinese pharmaceutical industry over the last thirty years. With a gross floorarea of more than 60,000 square meters and leading professional and academicforums, it attracts more than 1,900 exhibitors. PHARMCHINA is a diversifiedtrading and exchange platform for pharmaceutical companies. For moreinformation, please see http://www.pharmchina.com.cn .
About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of drugsand a licensed national seller of pharmaceutical items in the PRC. Lotusoperates its business through its two controlled entities: Liang FangPharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' currentdrug development is focused on the treatment of cerebro-cardiovascular disease,asthma and diabetes. Liang Fang sells drugs directly and indirectly throughits national sales channels to hospitals, clinics and drugs stores in 30provinces of the PRC.Time: April 24-26, 2010 Venue: International Convention Center, Xiamen Primary Booth: Liang Fang, Beijing Delegate Area
SOURCE Lotus Pharmaceuticals, Inc.